Skip to main content

IDWeek 2018

Phase 3 Trials Show Omadacycline’s Efficacy Against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections

Geographic Distribution of Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae Across Veterans Health Administration Outpatient Settings

Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms

Page 3 of 3
Results 21 - 23 of 23